TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription

Comparatively less toxic and more tolerated, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are recommendable for advanced non-small-cell lung cancer (NSCLC) patients with EGFR-sensitive mutations. Some EGFR wild-type patients with specific biomarkers also show a response to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Death Dis
Main Authors: Yuan, Weiwei, Xu, Wei, Li, Yan, Jiang, Wei, Li, Yue, Huang, Qiqing, Chen, Bo, Wu, Shuangshuang, Wang, Yu, Song, Weiwei, Zhao, Weihong, Wu, Jianqing
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6433914/
https://ncbi.nlm.nih.gov/pubmed/30911072
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-019-1519-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados